Table 2.
Comparison of Preoperative Risk Factors for Postoperative Death Within 1 Year After Tumor Recurrence
| Characteristics | Death Within 1 Year (23) | Death After 1 Year (83) | P value |
|---|---|---|---|
| Age, years | |||
| Average | 41.83 | 39.61 | 0.618 |
| Range | 24–68 | 18–70 | |
| Gender, n (%) | |||
| Female | 5 (21.7%) | 27 (32.5%) | 0.233 |
| Male | 18 (78.2%) | 56 (67.5%) | |
| Location, n (%) | |||
| Frontal | 8 (34.8%) | 30 (37.3%) | 0.953 |
| Temporal | 4 (17.4%) | 17 (20.5%) | |
| Multi | 6 (26.1%) | 22 (26.5%) | |
| Other | 5 (21.7%) | 14 (15.7%) | |
| Initial symptom, n (%) | |||
| Epilepsy | 17 (73.9%) | 39 (47.0%) | 0.019 |
| Other | 6 (26.1%) | 44 (53.0%) | |
| First diagnosed grade, n (%) | |||
| WHO II | 16 (69.6%) | 61 (73.5%) | 0.447 |
| WHO III | 7 (30.4%) | 22 (26.5%) | |
| First diagnosed pathology type, n (%) | |||
| Astrocytoma | 16 (69.6%) | 46 (55.4%) | 0.164 |
| Oligodendroglial | 7 (30.4%) | 37 (44.6%) | |
| Malignant transform, n (%) | |||
| Yes | 8 (34.8%) | 25 (30.1%) | 0.425 |
| No | 15 (65.2%) | 58 (69.9%) | |
| P53, n (%) | |||
| Mutant | 19 (82.6%) | 58 (69.9%) | 0.172 |
| Wide | 4 (17.4%) | 25 (30.1%) | |
| 1p/19q Codeletion, n (%) | |||
| yes | 6 (26.1%) | 41 (49.4%) | 0.038 |
| No | 17 (73.9%) | 42 (50.6%) | |
| IDH1, n (%) | |||
| Mutant | 15 (65.2%) | 58 (69.9%) | 0.425 |
| Wide | 8 (34.8%) | 25 (30.1%) | |
| ATRX, n (%) | |||
| Mutant | 15 (65.2%) | 51 (61.4%) | 0.470 |
| Wide | 8 (34.8%) | 32 (38.6%) | |
| Ki-67, n | |||
| Average | 16.13 | 17.95 | 0.870 |
| Range | 2–80 | 0–70 | |
| Adjuvant therapy, n (%) | |||
| Stupp | 10 (43.5%) | 58 (69.9%) | 0.019 |
| Other | 13 (56.5%) | 25 (30.1%) | |
| NLR, n (%) | |||
| ≤1.815 | 4 (17.4%) | 32 (38.6%) | 0.046 |
| >1.815 | 19 (82.6%) | 51 (61.4%) | |
| PLR, n (%) | |||
| ≤100.749 | 4 (17.4%) | 36 (43.4%) | 0.018 |
| >100.749 | 19 (82.6%) | 47 (56.6%) | |
| LMR, n (%) | |||
| ≤3.029 | 6 (26.1%) | 27 (32.5%) | 0.375 |
| >3.029 | 17 (73.9%) | 56 (67.5%) | |
| RDW, n% (%) | |||
| ≤13.4 | 11 (47.8%) | 59 (71.1%) | 0.035 |
| >13.4 | 12 (52.2%) | 24 (28.9%) | |
| Fib, g/L, n (%) | |||
| ≤2.80 | 10 (43.5%) | 58 (69.9%) | 0.019 |
| >2.80 | 13 (56.5%) | 25 (30.1%) | |
| DD, mg/L, n (%) | |||
| ≤0.187 | 11 (47.8%) | 61 (73.5%) | 0.020 |
| >0.187 | 12 (52.2%) | 22 (26.5%) | |
| TTR, days | |||
| Average | 1777.48 | 1814.64 | 0.908 |
| Range | 216–5425 | 177–6310 | |
IDH1 isocitrate dehydrogenase 1, ATRX alpha thalassemia/mental retardation syndrome X-linked, NLR the neutrophil-to-lymphocyte ratio, PLR the platelet-to-lymphocyte ratio, LMR the lymphocyte-to-monocyte ratio, RDW red blood cell distribution width, FIB fibrinogen, DD D-dimer, IQR interquartile range, TTR time to recurrence, OS overall survival